辉瑞依旧第一,GSK退出前10,礼来增速最高!——2024年各大MNC制药业务TOP 10汇总

药时代
13 Feb

正文共:6535字16图预计阅读时间:17分钟表:MNC制药业务收入TOP 10来源:各大药企财报从总排名来看,辉瑞依旧排名第一,同比增长7%,GSK退出前10,礼来以32%的最高增速新进入榜单第九名。1.辉瑞2024年辉瑞全年营收为636.27亿美元,同比增长7%。新冠产品全年贡献超110亿美元,但Comirnaty(疫苗)和Paxlovid(口服药)收入同比分别下降53%和46%,如果排除新冠...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10